Published in Scand J Rheumatol on January 01, 1987
Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann Rheum Dis (1990) 1.03
Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. Ann Rheum Dis (1990) 0.81
Risk factors for thrombosis in lupus patients. Ann Rheum Dis (1989) 0.78
Lupus anticoagulants in systemic lupus erythematosus: prevalence and clinical associations. Ann Rheum Dis (1990) 0.76
The antiphospholipid antibody dilemma. Clin Rheumatol (1990) 0.75
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) (1989) 3.13
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol (1972) 2.30
Somatic mutations in the variable regions of a human IgG anti-double-stranded DNA autoantibody suggest a role for antigen in the induction of systemic lupus erythematosus. J Exp Med (1991) 1.95
Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost (1996) 1.88
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum (1995) 1.80
Long-term followup of patients with Sjögren's syndrome. Arthritis Rheum (1996) 1.76
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J (1999) 1.58
The human thymus microenvironment: heterogeneity detected by monoclonal anti-epithelial cell antibodies. Immunology (1985) 1.56
Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis (1998) 1.55
Sjögren's syndrome in patients with chronic idiopathic axonal polyneuropathy. J Neurol Neurosurg Psychiatry (1997) 1.54
Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis (1992) 1.54
Heat treatment of serum and plasma induces false positive results in the antiphospholipid antibody ELISA. J Rheumatol (1990) 1.53
Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A (1977) 1.52
Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost (2003) 1.52
Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood (1995) 1.50
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Heterogeneity of epithelial cells in the human thymus. An ultrastructural study. Cell Tissue Res (1984) 1.47
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
IgA-deposits in cutaneous blood-vessel walls and mesangium in Henoch-Schönlein syndrome. Lancet (1973) 1.40
C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost (2001) 1.40
[Clinical thinking and decision-making in practice. A patient with arthritis, skin lesions and a perforated nasal septum]. Ned Tijdschr Geneeskd (1999) 1.38
Prevention of relapses in systemic lupus erythematosus. Lancet (1995) 1.33
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost (2000) 1.32
Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med (1978) 1.30
Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis (1995) 1.29
Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol (1991) 1.28
A reduced organic carbon component in martian basalts. Science (2012) 1.28
Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem (1994) 1.27
Inactivation of kallikrein in human plasma. J Clin Invest (1983) 1.27
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med (1978) 1.26
Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res (1974) 1.26
Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost (2001) 1.26
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest (1997) 1.23
The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) (2002) 1.22
Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum (1987) 1.21
Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest (1998) 1.21
The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) (2002) 1.18
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood (1995) 1.16
Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum (1986) 1.15
Lupus anticoagulant: revival of an old phenomenon. Clin Exp Rheumatol (1986) 1.14
Long-term course of tear gland function in patients with keratoconjunctivitis sicca and Sjögren's syndrome. Br J Ophthalmol (1997) 1.13
Occurrence of vascular IgA deposits in clinically normal skin of patients with renal disease. Kidney Int (1976) 1.13
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis (1983) 1.10
Large vessel occlusion and gangrene in systemic lupus erythematosus and "lupus-like" disease. A report of six cases. J Rheumatol (1986) 1.10
Treatment of Wegener's granulomatosis with cyclosporin. Ann Rheum Dis (1987) 1.10
Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry (1980) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet (1999) 1.07
A human systemic lupus erythematosus-related anti-cardiolipin/single-stranded DNA autoantibody is encoded by a somatically mutated variant of the developmentally restricted 51P1 VH gene. J Immunol (1992) 1.06
Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. J Clin Invest (1983) 1.05
Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem (1983) 1.04
Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med (1985) 1.04
Presence of oestrogen receptors in human blood mononuclear cells and thymocytes. Acta Endocrinol (Copenh) (1986) 1.04
Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost (1998) 1.03
Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost (1996) 1.03
Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med (1981) 1.02
Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis (1993) 1.01
Identification and in situ localization of the "thymic nurse cell" in man. J Immunol (1983) 1.01
Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest (1988) 1.01
Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum (2000) 1.00
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost (2002) 1.00
Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI. J Biol Chem (1978) 0.99
Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry (1988) 0.99
Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein. J Biol Chem (1980) 0.99
An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature (1979) 0.98
Multinucleate giant cells in sublabial salivary gland tissue in Sjögren's syndrome. A diagnostic pitfall. Virchows Arch A Pathol Anat Histopathol (1984) 0.97
The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem (1988) 0.97
Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J Clin Invest (1978) 0.97
Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor. Proc Natl Acad Sci U S A (1990) 0.96
Morphometric study of histological changes in sublabial salivary glands due to aging process. J Clin Pathol (1986) 0.95
Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis (1989) 0.95
Factor VIII and von Willebrand factor. Thromb Haemost (1998) 0.95
Immunological studies of prekallikrein, kallikrein, and high-molecular-weight kininogen in normal and deficient plasmas and in normal plasma after cold-dependent activation. J Lab Clin Med (1980) 0.94
Dimers of beta 2-glycoprotein I mimic the in vitro effects of beta 2-glycoprotein I-anti-beta 2-glycoprotein I antibody complexes. J Biol Chem (2000) 0.94
How unique is the thymus? Conditioned media from thymus and tonsil epithelial cultures share biological activities in T-cell maturation. Clin Immunol Immunopathol (1981) 0.94
Aging, physical conditioning, and exercise-induced changes in hemostatic factors and reaction products. J Appl Physiol (1985) (2000) 0.94
The localization of heparin-binding fragments on human C4b-binding protein. J Immunol (1990) 0.94
Probabilistic classification of hemophilia A carriers by discriminant analysis. Thromb Res (1976) 0.93
Lymphocyte status of lymph node and blood in acquired immunodeficiency syndrome (AIDS) and AIDS-related complex disease. J Pathol (1985) 0.93
Renal infarction associated with anti-phospholipid antibodies in systemic lupus erythematosus and "lupus-like" disease. J Urol (1988) 0.93
Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost (1992) 0.92
Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem (1992) 0.92